香港股市 將在 8 小時 2 分鐘 開市

MRK Jul 2023 80.000 put

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
0.8200-0.0900 (-9.89%)
市場開市。 截至 03:42PM EST。
全螢幕
前收市價0.9100
開市0.8400
買盤0.7500
賣出價0.8500
拍板80.00
到期日2023-07-21
今日波幅0.8200 - 0.8400
合同範圍
成交量50
未平倉合約101
  • Insider Monkey

    12 Safe Stocks to Buy For Long-Term

    In this article, we take a look at 12 safe stocks to buy for the long-term according to hedge funds. You can skip our detailed analysis of safe stocks and go directly to read 5 Safe Stocks to Buy According to Hedge Funds. Even if there are many indications that the macro environment will remain […]

  • Benzinga

    Merck's Keytruda Plus Chemo Combo Aces Late-Stage Study In Advanced Endometrial Cancer Patients

    Merck & Co Inc's (NYSE: MRK) Phase 3 NRG-GY018 trial evaluating Keytruda (pembrolizumab) combined with standard-of-care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival (PFS). The trial covered patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status. Related: Merck's Keytruda Phase 3 Trial Meets Primary Endpoint In Gastric Cancer Patients. The treatment regime included Keytruda + Chemo combo, then continued

  • Benzinga

    Merck's Oral COVID-19 Treatment Might Be Linked To Spreading Mutations, Study Shows

    According to some researchers, Merck & Co’s (NYSE: MRK) COVID-pill is giving rise to new mutations of the COVID-19 virus in some patients. Mutations linked to Merck’s COVID-19 oral treatment Lagevrio (Molnupiravir) have been identified in viral samples taken from several patients, according to a preprint study from researchers in the U.S. and at the Francis Crick Institute, Imperial College London, and other U.K. institutions. Also Read: Merck Beats On Q4 earnings, Anticipates Almost 80% Decline